Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,147,099 papers from all fields of science
Search
Sign In
Create Free Account
dacomitinib
Known as:
(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide
A highly selective, orally bioavailable small-molecule inhibitor of the HER family of tyrosine kinases with potential antineoplastic activity…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
NCIt Antineoplastic Agent Terminology
PF 00299804
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Dacomitinib for Advanced Non–Small-Cell Lung Cancer
A. Tsao
2018
Corpus ID: 91919045
In a prior phase II study, the second-generation, irreversible, epidermal growth factor–receptor tyrosine kinase inhibitor (TKI…
Expand
2017
2017
Dacomitinib, Superior Efficacy But Inferior Safety Profile to Frontline Therapy Gefitinib
C. Bennett
2017
Corpus ID: 80317860
LBA9007 Continued on page 27
2017
2017
Dacomitinib Delayed Progression for NSCLC, Increased Adverse Events
L. Lawrence
2017
Corpus ID: 155732525
Dacomitinib delayed progression of EGFR-positive non–small-cell lung cancer, but led to more adverse events compared with…
Expand
2017
2017
Dacomitinib Tops Gefitinib in First-Line EGFR-Mutant NSCLC
D. Levitan
2017
Corpus ID: 146091451
The second-generation EGFR tyrosine kinase inhibitor dacomitinib significantly improved progression-free survival over gefitinib…
Expand
2016
2016
Preparation method and key intermediate of dacomitinib
翟富民
,
花海堂
,
胡玉乾
,
包华兰
2016
Corpus ID: 146071246
The invention discloses a preparation method and key intermediate of an antitumor drug dacomitinib, wherein the preparation…
Expand
Review
2014
Review
2014
TITLE : Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
C. Rolfo
,
E. Giovanetti
,
+17 authors
R. Rosell
2014
Corpus ID: 260603751
Please cite this article as: Rolfo, C., Giovanetti, E., Hong, D.S., Bivona, T., Raez, L.E., Bronte, G., Buffoni, L., Reguart, N…
Expand
Review
2013
Review
2013
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
M. Boyer
,
P. Jänne
,
+9 authors
V. Antić
2013
Corpus ID: 53525528
Background: Dacomitinib (PF-00299804) is an irreversible pan-HER tyrosine kinase inhibitor. We describe the rationale and design…
Expand
2013
2013
Der Einsatz von Tyrosinkinase-Inhibitoren bei aktivierenden EGFR-Mutationen in der Erstlinientherapie beim fortgeschrittenen nicht-kleinzelligen Lungen-karzinom ( NSCLC ) – aktueller Stand und…
R. Wiewrodt
,
M. Serke
,
C. Grohé
,
W. Brückl
2013
Corpus ID: 207811390
Trotz großer Fortschritte in Forschung und Therapie in den letzten Jahren sind Lungenkarzinome nach wie vor die häufigste…
Expand
2012
2012
Dacomitinib. Pan-ErbB inhibitor, Oncolytic
K. Hedgethorne
,
Paul H. Huang
2012
Corpus ID: 74454639
The ErbB receptor tyrosine-protein kinase family is aberrantly activated in a variety of cancer types and signaling through these…
Expand
2012
2012
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
D. Karikios
,
M. Boyer
2012
Corpus ID: 56066595
The EGFR has become an important target in lung cancer treatment. Reversible inhibitors of this receptor have been shown to…
Expand